Pharmacy World and Science

, Volume 26, Issue 2, pp 107–109 | Cite as

Effect of gentamicin on serum digoxin level in patients with congestive heart failure

  • Hussien Omer Alkadi
  • Majed Alwan Nooman
  • Yahia Ahmed Raja'a


Objective: Gentamicin is frequently used to treat infectious diseases in patients receiving digitalis therapy. The aim of this study is to evaluate the effect of gentamicin on serum digoxin level.

Method: Twenty-four diabetic patients and patients with congestive heart failure and twelve normal healthy volunteers were enrolled in this study. The patients received digoxin treatment 0.25 mg/day. Gentamicin in a dose of 80 mg i.m. twice a day for 7 days was prescribed for these patients to treat chest infection. Serum digoxin and creatinine levels were determined before and after gentamicin administration.

Results: Gentamicin induced a significant increase in serum digoxin level of diabetic patients and patients with congestive heart failure. Serum creatinine level increased significantly before and after i.m. injection of gentamicin.

Conclusion: The present study indicated that increase serum digoxin level when combined with gentamicin should be considered a risk factor for digitalis toxicity.

Congestive heart failure Diabetes Digoxin Drug–drug interaction Gentamicin Serum digoxin level 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Staneva SD, Kristeva E, Prodanova K. Some pharmacokinetic and pharmacodynamic interactions between digoxin and gentamicin. Eur J Drug Met Pharmacol 1992; 17: 1-8.Google Scholar
  2. 2.
    Doherty JM. A digoxin-antibiotics drug interaction. NEJM 1981; 305: 27-8.Google Scholar
  3. 3.
    Alkadi HO. Effect of some antimicrobial agents on digoxin pharmacokinetics. [Dissertation], Zagazig University, Egypt, 1994; 65-82.Google Scholar
  4. 4.
    Gault MH. Digoxin metabolism. Clin Chem 1987; 33: 1052-3.Google Scholar
  5. 5.
    Koren G, McLeods SM. Characteristics of the digoxin verapamil interaction in the rat kidney. Res Commun Chem Pathol Pharmacol 1984; 45: 3-18.Google Scholar
  6. 6.
    Schinkel AH, Wagenaar E, Van Deemter L, Mol CA, Borst P. Absence of the mdrla P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 1995; 96: 1698-705.Google Scholar
  7. 7.
    Joel GH, Lee EL, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics. Tenth ed. New York: McGraw-Hill, 2001; 1225 pp.Google Scholar
  8. 8.
    Ramesh K, Goyal Sunita MJ, Jayessh JS, Dave KC, Mehata HC. Altered digoxin levels in diabetic patients with congestive cardiac failure. Indian J Pharmacol 1987; 19: 117-23.Google Scholar
  9. 9.
    Godfraind T. Cardiac glycosides receptors in the heart. Biochem Pharmacol 1975; 24: 823-7.Google Scholar
  10. 10.
    Godfraind T, Noel F, Finet M. Calcium regulatory mechanisms involved in the inotropic effect of digitalis. J Mol Cell Cardiol 1983; 15(Suppl. 2): 43.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Hussien Omer Alkadi
    • 1
  • Majed Alwan Nooman
    • 1
  • Yahia Ahmed Raja'a
    • 1
  1. 1.Pharmacology and Therapeutic Department, Faculty of Medicine and Health SciencesSana'a University, Member of ESCPSana'aYemen

Personalised recommendations